Recent Progress in MRNA Cancer Vaccines

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2024 Jan 29

PMID 38282471

Authors

Ruhui Yao

Chunyuan Xie

Xiaojun Xia

Affiliations

Soon will be listed here.

Abstract

The research and development of messenger RNA (mRNA) cancer vaccines have gradually overcome numerous challenges through the application of personalized cancer antigens, structural optimization of mRNA, and the development of alternative RNA-based vectors and efficient targeted delivery vectors. Clinical trials are currently underway for various cancer vaccines that encode tumor-associated antigens (TAAs), tumor-specific antigens (TSAs), or immunomodulators. In this paper, we summarize the optimization of mRNA and the emergence of RNA-based expression vectors in cancer vaccines. We begin by reviewing the advancement and utilization of state-of-the-art targeted lipid nanoparticles (LNPs), followed by presenting the primary classifications and clinical applications of mRNA cancer vaccines. Collectively, mRNA vaccines are emerging as a central focus in cancer immunotherapy, offering the potential to address multiple challenges in cancer treatment, either as standalone therapies or in combination with current cancer treatments.

Citing Articles

Adopting tomorrow's therapies today: a perspective review of adoptive cell therapy in lung cancer.

Abodunrin F, Olson D, Emehinola O, Bestvina C Ther Adv Med Oncol. 2025; 17:17588359251320280.

PMID: 40012708 PMC: 11863254. DOI: 10.1177/17588359251320280.

The Past, Present, and Future of Cervical Cancer Vaccines.

Lien A, Johnson G, Guan T, Burns C, Parker J, Dong L Vaccines (Basel). 2025; 13(2).

PMID: 40006746 PMC: 11861678. DOI: 10.3390/vaccines13020201.

Revolutionizing Nanovaccines: A New Era of Immunization.

Saleh M, El-Moghazy A, Elgohary A, Saber W, Helmy Y Vaccines (Basel). 2025; 13(2).

PMID: 40006673 PMC: 11860605. DOI: 10.3390/vaccines13020126.

Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy.

Imani S, Li X, Chen K, Maghsoudloo M, Jabbarzadeh Kaboli P, Hashemi M Front Cell Infect Microbiol. 2025; 14:1501010.

PMID: 39902185 PMC: 11788159. DOI: 10.3389/fcimb.2024.1501010.

Cancer vaccines: platforms and current progress.

Lei W, Zhou K, Lei Y, Li Q, Zhu H Mol Biomed. 2025; 6(1):3.

PMID: 39789208 PMC: 11717780. DOI: 10.1186/s43556-024-00241-8.

References

Tenzer S, Docter D, Kuharev J, Musyanovych A, Fetz V, Hecht R . Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol. 2013; 8(10):772-81. DOI: 10.1038/nnano.2013.181. View

Amaya L, Grigoryan L, Li Z, Lee A, Wender P, Pulendran B . Circular RNA vaccine induces potent T cell responses. Proc Natl Acad Sci U S A. 2023; 120(20):e2302191120. PMC: 10193964. DOI: 10.1073/pnas.2302191120. View

Henderson J, Ujita A, Hill E, Yousif-Rosales S, Smith C, Ko N . Cap 1 Messenger RNA Synthesis with Co-transcriptional CleanCap Analog by In Vitro Transcription. Curr Protoc. 2021; 1(2):e39. DOI: 10.1002/cpz1.39. View

Sahin U, Oehm P, Derhovanessian E, Jabulowsky R, Vormehr M, Gold M . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020; 585(7823):107-112. DOI: 10.1038/s41586-020-2537-9. View

Pietropaolo V, Prezioso C, Moens U . Role of Virus-Induced Host Cell Epigenetic Changes in Cancer. Int J Mol Sci. 2021; 22(15). PMC: 8346956. DOI: 10.3390/ijms22158346. View

Boczkowski D, Nair S, Snyder D, Gilboa E . Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996; 184(2):465-72. PMC: 2192710. DOI: 10.1084/jem.184.2.465. View

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

Weissman D, Kariko K . mRNA: Fulfilling the Promise of Gene Therapy. Mol Ther. 2015; 23(9):1416-7. PMC: 4817894. DOI: 10.1038/mt.2015.138. View

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

10.

Gubin M, Zhang X, Schuster H, Caron E, Ward J, Noguchi T . Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014; 515(7528):577-81. PMC: 4279952. DOI: 10.1038/nature13988. View

11.

Sahin U, Tureci O . Personalized vaccines for cancer immunotherapy. Science. 2018; 359(6382):1355-1360. DOI: 10.1126/science.aar7112. View

12.

Igyarto B, Jacobsen S, Ndeupen S . Future considerations for the mRNA-lipid nanoparticle vaccine platform. Curr Opin Virol. 2021; 48:65-72. PMC: 8065267. DOI: 10.1016/j.coviro.2021.03.008. View

13.

Qiu M, Tang Y, Chen J, Muriph R, Ye Z, Huang C . Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2022; 119(8). PMC: 8872770. DOI: 10.1073/pnas.2116271119. View

14.

Blass E, Ott P . Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021; 18(4):215-229. PMC: 7816749. DOI: 10.1038/s41571-020-00460-2. View

15.

He Q, Gao H, Tan D, Zhang H, Wang J . mRNA cancer vaccines: Advances, trends and challenges. Acta Pharm Sin B. 2022; 12(7):2969-2989. PMC: 8942458. DOI: 10.1016/j.apsb.2022.03.011. View

16.

Matsushita H, Vesely M, Koboldt D, Rickert C, Uppaluri R, Magrini V . Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012; 482(7385):400-4. PMC: 3874809. DOI: 10.1038/nature10755. View

17.

Silva J, Bitencourt Rodrigues K, Formoso Pelegrin G, Sales N, Muramatsu H, Silva M . Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice. Sci Transl Med. 2023; 15(686):eabn3464. DOI: 10.1126/scitranslmed.abn3464. View

18.

Fiedler K, Lazzaro S, Lutz J, Rauch S, Heidenreich R . mRNA Cancer Vaccines. Recent Results Cancer Res. 2017; 209:61-85. DOI: 10.1007/978-3-319-42934-2_5. View

19.

Cheng L, Wang Y, Du J . Human Papillomavirus Vaccines: An Updated Review. Vaccines (Basel). 2020; 8(3). PMC: 7565290. DOI: 10.3390/vaccines8030391. View

20.

Corbett K, Edwards D, Leist S, Abiona O, Boyoglu-Barnum S, Gillespie R . SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020; 586(7830):567-571. PMC: 7581537. DOI: 10.1038/s41586-020-2622-0. View